Literature DB >> 9628713

Why are physicians not prescribing diuretics more frequently in the management of hypertension?

M Moser1.   

Abstract

Diuretics have again been recommended by the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) as one of the first-choice medications in the management of hypertension. This recommendation is based on the results of numerous randomized, diuretic-based, long-term controlled clinical trials that have demonstrated a reduction in both cerebrovascular and cardiovascular morbidity. Despite this and other national recommendations, the use of diuretics has steadily decreased over the past 15 years. Reasons include heavy promotion of other medications and the perception that diuretics produce adverse metabolic effects and do not reduce coronary heart disease events. Data, however, indicate that (1) changes in glucose and cholesterol metabolism are minor, especially with the smaller doses now being used; (2) cardiovascular morbidity and mortality have been reduced in hypertensive patients, even in those with hyperlipidemia or diabetes, when diuretics are used; and (3) concerns about hypokalemia-induced arrhythmias have been overstated. While special indications exist for other medications in the treatment of hypertension, for example, use of an angiotensin-converting enzyme inhibitor (usually in addition to a diuretic) for a patient with heart failure or diabetic nephropathy, most patients, including those with hyperlipidemia or glucose intolerance, can be effectively treated with a diuretic as initial therapy or as part of a combination regimen. Diuretics should be used more not less frequently; use of diuretics would reduce the number of resistant hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628713     DOI: 10.1001/jama.279.22.1813

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  26 in total

Review 1.  Old antihypertensive agents-diuretics and beta-blockers: do we know how and in whom they lower blood pressure?

Authors:  D A Sica
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 2.  The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis.

Authors:  Amy B Cadwallader; Xavier de la Torre; Alessandra Tieri; Francesco Botrè
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 3.  Concluding remarks. Pursuit of the optimal outcome in hypertension.

Authors:  L Hansson
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 4.  Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems.

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-17       Impact factor: 3.000

5.  Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians.

Authors:  Peter A Ubel; Christopher Jepson; David A Asch
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

6.  Cost-effectiveness in Preventive Cardiology.

Authors:  William S. Weintraub
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-08

Review 7.  Diuretic-related side effects: development and treatment.

Authors:  Doemnic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-09       Impact factor: 3.738

8.  Prescribing patterns of diuretics in multi-drug antihypertensive regimens.

Authors:  Hardeep Singh; Michael L Johnson
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-02       Impact factor: 3.738

9.  Understanding uncontrolled hypertension: is it the patient or the provider?

Authors:  Adam J Rose; Dan R Berlowitz; Michelle B Orner; Nancy R Kressin
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-12       Impact factor: 3.738

Review 10.  Rationale for combination therapy in the management of hypertension.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.